LungLife AI Inc Cash Flow Conversion Efficiency
LungLife AI Inc cash flow conversion efficiency. Based on the latest financial reports, LungLife AI Inc (LLAI) has a cash flow conversion efficiency ratio of -0.245x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.94 Million ≈ $-236.53 USD) by net assets (GBX7.93 Million ≈ $965.22 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LungLife AI Inc (2018–2023)
Cash flow conversion efficiency of LungLife AI Inc from 2018 to 2023. This chart illustrates how LungLife AI Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LLAI live share price for real-time trading data and today's change.
LungLife AI Inc Cash Flow Conversion Ratio Explained
LungLife AI Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LungLife AI Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LungLife AI Inc ranked by their cash flow conversion efficiency. Also see LLAI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Isaac Engineering Co. Ltd.
KQ:351330
|
0.182x |
|
Endor AG
MU:E2N
|
691.016x |
|
ECD Automotive Design Inc
NASDAQ:ECDA
|
0.126x |
|
Worldsec Ltd
LSE:WSL
|
-0.052x |
|
MediaZest plc
LSE:MDZ
|
0.255x |
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
0.080x |
|
Eenergy Group PLC
LSE:EAAS
|
1.306x |
|
Distil Plc
LSE:DIS
|
-0.129x |
Annual Cash Flow Conversion Efficiency for LungLife AI Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of LungLife AI Inc from 2018 to 2023. Review LLAI financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX7.91 Million ≈ $962.78 |
GBX-5.02 Million ≈ $-610.79 |
-0.634x | -42.62% |
| 2022-12-31 | GBX13.14 Million ≈ $1.60K |
GBX-5.84 Million ≈ $-711.17 |
-0.445x | -18.78% |
| 2021-12-31 | GBX20.13 Million ≈ $2.45K |
GBX-7.54 Million ≈ $-917.26 |
-0.375x | -154.46% |
| 2020-12-31 | GBX19.53 Million ≈ $2.38K |
GBX-2.87 Million ≈ $-349.69 |
-0.147x | -130.12% |
| 2019-12-31 | GBX-6.80 Million ≈ $-827.11 |
GBX-3.32 Million ≈ $-404.19 |
0.489x | -29.30% |
| 2018-12-31 | GBX-3.10 Million ≈ $-377.22 |
GBX-2.14 Million ≈ $-260.72 |
0.691x | -- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more